Get the Stockscreener App
1.38
4.83%
-0.07
After Hours:
1.44
0.06
+4.35%
Novabridge Biosciences Adr stock is traded at $1.38, with a volume of 6.61M.
It is down -4.83% in the last 24 hours and down -28.50% over the past month.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
See More
Previous Close:
$1.45
Open:
$1.43
24h Volume:
6.61M
Relative Volume:
13.21
Market Cap:
$159.59M
Revenue:
$232.79M
Net Income/Loss:
$-88.69M
P/E Ratio:
-3.1229
EPS:
-0.4419
Net Cash Flow:
-
1W Performance:
-13.75%
1M Performance:
-28.50%
6M Performance:
-47.73%
1Y Performance:
+0.00%
1-Day Range:
$1.315
$1.44
1-Week Range:
$1.315
$1.64
52-Week Range:
$1.315
$5.19
Novabridge Biosciences Adr Stock (NBP) Company Profile
Name
Novabridge Biosciences Adr
Sector
Industry
Phone
-
Address
-
Compare NBP vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBP
Novabridge Biosciences Adr
|
1.38 | 159.59M | 232.79M | -88.69M | 0 | -0.4419 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Novabridge Biosciences Adr Stock (NBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-26 | Resumed | H.C. Wainwright | Buy |
| Oct-03-25 | Initiated | Leerink Partners | Outperform |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Dec-09-21 | Initiated | Siebert Williams Shank | Buy |
| Jun-02-21 | Initiated | Daiwa Securities | Buy |
| Mar-15-21 | Initiated | Needham | Buy |
| Mar-03-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-25-21 | Initiated | Piper Sandler | Overweight |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-20 | Initiated | China Renaissance | Buy |
| Feb-11-20 | Initiated | Jefferies | Buy |
View All
Novabridge Biosciences Adr Stock (NBP) Latest News
Empowering Investor Success - Morningstar
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
Novabridge Biosciences ADR (NBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Novabridge Biosciences ADR (NBP) Cash Flow - TradingKey
Novabridge Biosciences ADR (NBP) Institutional Confidence - TradingKey
NBP|Novabridge Biosciences ADR|Price:1.840|Chg%:+0.070 - TradingKey
Novabridge Biosciences ADR (NBP) Balance Sheet - TradingKey
Novabridge Biosciences ADR (NBP) Income Statement - TradingKey
NBP|Novabridge Biosciences ADR|Price:1.790| - TradingKey
Novabridge Biosciences ADR (NBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Novabridge Biosciences ADR (NBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Novabridge Biosciences ADR (NBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Novabridge Biosciences ADR (NBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NBP|Novabridge Biosciences ADR|Price:1.770| - TradingKey
Novabridge Biosciences ADR (NBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NovaBridge Biosciences SVP sells $3,991 in ordinary shares - Investing.com
NBPNovaBridge Biosciences ADR Latest SEC Filings - Finviz
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer - Barchart.com
NovaBridge Biosciences Sponsored ADR Actuals & Estimates (NASDAQ:NBP) - TradingView
Novabridge Biosciences ADR (NBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Novabridge Biosciences ADR - TradingKey
NovaBridge Biosciences (NBP) corrects major holder stakes in 20-F/A filing - Stock Titan
NovaBridge Biosciences stock surges on FDA Fast Track nod By Investing.com - Investing.com South Africa
NovaBridge Biosciences stock surges on FDA Fast Track nod - Investing.com
Number of shareholders of NovaBridge Biosciences Sponsored ADR – GETTEX:0VY - TradingView
NovaBridge Biosciences SVP Claire Xu sells $13,766 in shares By Investing.com - Investing.com India
NovaBridge Biosciences SVP Claire Xu sells $13,766 in shares - Investing.com
Sean Cao, NovaBridge Biosciences chief BD officer, sells $42,584 in shares - Investing.com
TradingKey - TradingKey
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
NovaBridge Biosciences president buys $577,300 in company shares By Investing.com - Investing.com India
NovaBridge Biosciences president buys $577,300 in company shares - Investing.com
NovaBridge appoints Mark Hagler as president, chief commercial officer - Investing.com
NovaBridge Biosciences (NASDAQ: NBP) posts 2025 loss, extends cash runway to 2028 - Stock Titan
NovaBridge gets FDA nod for accelerated approval path for givastomig - Investing.com
NovaBridge reports positive Phase 2a data for eye disease drug - Investing.com
NBP Stock Price and Chart — NASDAQ:NBP - TradingView
BTIG Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
What is the current Price Target and Forecast for NovaBridge Biosciences (NBP) - Zacks Investment Research
NovaBridge Biosciences (0VY.F) stock price, news, quote and history - Yahoo Finance Singapore
What date does NovaBridge Biosciences's (NBP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
NBP Stock Price | Analyst Target 9.00 & Consensus - eToro
NBP Options Overview History for Novabridge Biosciences ADR Stock - Barchart.com
I-Mab stock price target raised to $9 from $7 at BTIG on strategic shift - Investing.com
NBP: Transforming into a global biotech, rebranding, and pursuing dual NASDAQ/HKEX listing - TradingView
NBP: Jeva Stomach demonstrates high efficacy and safety, with broad expansion plans and strong financial runway - TradingView
IMAB SEC FilingsI-Mab 10-K, 10-Q, 8-K Forms - Stock Titan
NBP: Reduced net loss and accelerated givastomig progress position I-Mab for key milestones - TradingView
I-MAB American (IMAB) Stock Price, News & Analysis - Stock Titan
NBP: Lead asset givastomig shows strong efficacy and safety in gastric cancer, with key data readouts in 2024–2025 - TradingView
Novabridge Biosciences Adr Stock (NBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):